

RFA's

- **COLLABORATIVE STUDIES ON ALZHEIMER AND RELATED DISEASES**

Applications due December 21, 2004

- **ALZHEIMER'S DISEASE CLINICAL SCIENTIST DEVELOPMENT AWARD**

Applications due January 25, 2005

Electronic Submission and Center Grant applications

- All Type 5s mailed to new address (DEAS) for Scanning
- CD ROM submission of Appendix Material for Type 2s and Type 5s - mail to NIA

NIH GUIDE FOR GRANTS AND CONTRACTS

Vol. 12, No. 12 December 9 1983

AVAILABILITY OF REQUEST FOR APPLICATION: RFA ALZHEIMER DISEASE RESEARCH CENTERS

84-AGO 1

NATIONAL INSTITUTE ON AGING

Application Receipt Date: March 20, **1984** Letter of Intent Receipt Date:
February **15,1984**



Khachaturian

(CNN)


First Five AD Center Directors -1984



John Growdon
Harvard



Donald Price
Johns Hopkins



Robert Katzman
UC San Diego



Kenneth Davis
Mount Sinai



Caleb Finch
U Southern California

CURRENTLY ACTIVE CENTERS WITH FOUNDING DATES

<u>ADRCs – P50</u>			<u>ADCCs – P30</u>	
Harvard University 1984	Duke University 1985	University of Michigan 1989	U Texas Southwestern 1988	University of Pennsylvania 1991
Johns Hopkins University 1984	University of Kentucky 1985	Mayo Clinic 1990	New York University 1990	Boston University 1996
Mount Sinai Medical School 1984	University of Pittsburgh 1985	University of Alabama 1991	Oregon Health Science University 1990	Northwestern University 1996
U California San Diego 1984	University of Washington 1985	U California Los Angeles 1991	Indiana University 1991	Stanford University 2000
U Southern California 1984	Washington University 1985	U California Irvine 2000	Rush Presbyterian St Lukes 1991	Arizona Alzheimer's Center 2001
Case Western Reserve University 1988	Columbia University 1988	U California San Francisco 2004	U California Davis 1991	University of Arkansas 2001

Random ADC Statistics

- 30 ADCs presently (27 fully, 3 temporary)
- 35 ADCs since 1984
- 5 ADCs discontinued
- 4 ADCs have been P30 and P50 at different times
- 55 Directors since 1984
- 16 ADCs with founding Director still serving
- 2 – 1984 ADCs with founding Director still serving
- 1 ADC has had 5 Directors since 1985
- 1 person has served as Director for 2 ADCs

Report on the Clinico-Pathological Correlations in the Lewy Body Dementias: NIA-NINDS Planning Workshop September 20-21, 2004

- Encourage Newcastle Group to publish results of Consensus Conference
- Promote a series of working groups to propose hypothesis-driven studies of
 - Visuospatial assessment in dementia
 - Assessment of fluctuations in dementia
 - Sleep assessment
 - Assessment of autonomic function
- Develop best practices for the neuropathological workup (including biochemistry) of DLB, PD, PDD using the Udall Centers and Alzheimer's Centers

- Collect family histories and blood samples from patients with affected first degree relatives
- Harmonize genetic studies of LB diseases funded by NIA and NINDS with similar efforts in Udall Centers to develop synergies
- Consider a program to test compounds that target dementia in AD, DLB, PDD, etc.
- Pursue studies of possible biomarkers such as neuroimaging, sleep measurements as well as CSF, plasma and urine measurements

The background features a wireframe head in profile, facing right, with numerous glowing orange nodes and connecting lines. To the right of the head is a green wireframe globe. The text 'World Parkinson Congress' is overlaid on the globe in white.

World Parkinson Congress

February 22-26, 2006

Convention Center – Washington, DC

World Parkinson Congress, Inc.

Web: www.worldPDcongress.org

Tel: 800.457.6676

Report on the Clinico-Pathological Correlations in the Lewy Body Dementias: NIA-NINDS Planning Workshop - September 20-21, 2004

- Encourage Newcastle Group to publish results of Consensus Conference
- Promote a series of working groups to propose hypothesis-driven studies of
 - Visuospatial assessment in dementia
 - Assessment of fluctuations in dementia
 - Sleep assessment
 - Assessment of autonomic function
- Develop best practices for the neuropathological workup of DLB, PD, PDD through the Udall Centers and Alzheimer's Centers, including biochemistry
- Collect family histories and blood samples from patients with affected first degree relatives
- Harmonize genetic studies of LB diseases funded by NIA and NINDS with similar efforts in Udall Centers to develop synergies
- A program to test compounds that target dementia in AD, DLB, PDD, etc. should be considered
- Biomarkers should be pursued such as neuroimaging, sleep measurements as well as CSF, plasma and urine measurements